Search Results - "Radinov, A"

PB2040: INTERRELATION BETWEEN JAK2 V617F MUTATION AND THE INCIDENCE OF THROMBOTIC EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS by Nikolova, D., Yordanov, A., Damyanova, V., Radinov, A.

Get full text

Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings by Nikolova D., Yordanov A., Radinov A.

“…Introduction: Azacitidine is one of the hypomethylating agents available for the treatment of elderly patients with myelodysplastic syndrome (MDS) or acute…”
Get full text

Gaucher Disease Type I: A Case Report by Nikolova, D., Yordanov, A., Damyanova, V., Yavorova, A., Radinov, A.

“…Abstract Gaucher disease (GD) is a multi-systemic disease with a low population frequency. It is a lysosomal storage disorder (LSD) that causes accumulation of…”
Get full text

Janus kinase V617F mutation detection in patients with myelofibrosis by Nikolova, D, Yordanov, A, Damyanova, V, Radinov, A, Toncheva, D

“…Abstract Myelofibrosis (MF) is characterized by a presence of an extra fibrous tissue in the bone marrow and additional hematopoiesis. The somatic mutation in…”
Get full text

Prognostic factors influencing outcome after therapy with brentuximab vedotin in patients with relapsed or refractory Hodgkin’s lymphoma by Goranova-Marinova, V.S., Ignatova, K., Ganeva, P., Spasov, E., Arnaudov, G., Micheva, I., Gercheva, L., Radinov, A., Petrova, R., Tzvetkova, G., Hadzhiev, E., Bogdanov, L., Tzvetkov, N., Spasov, B., Grudeva-Popova, Z., Tumbeva, D.

Get full text

1073P - Prognostic factors influencing outcome after therapy with brentuximab vedotin in patients with relapsed or refractory Hodgkin’s lymphoma by Goranova-Marinova, V.S., Ignatova, K., Ganeva, P., Spasov, E., Arnaudov, G., Micheva, I., Gercheva, L., Radinov, A., Petrova, R., Tzvetkova, G., Hadzhiev, E., Bogdanov, L., Tzvetkov, N., Spasov, B., Grudeva-Popova, Z., Tumbeva, D.

“…Brentuximab Vedotin (BV) treatment has improved the prognosis and survival of patients with Hodgkin’s lymphoma, relapsed after stem cell transplantation or…”
Get full text

1073PPrognostic factors influencing outcome after therapy with brentuximab vedotin in patients with relapsed or refractory Hodgkin’s lymphoma by Goranova-Marinova, V S, Ignatova, K, Ganeva, P, Spasov, E, Arnaudov, G, Micheva, I, Gercheva, L, Radinov, A, Petrova, R, Tzvetkova, G, Hadzhiev, E, Bogdanov, L, Tzvetkov, N, Spasov, B, Grudeva-Popova, Z, Tumbeva, D

“…Abstract Background Brentuximab Vedotin (BV) treatment has improved the prognosis and survival of patients with Hodgkin’s lymphoma, relapsed after stem cell…”
Get full text

Stimulating effect of an oral polybacterial immunomodulator on the proliferative activity of guinea pig lymphocytes by Markova, Roumiana, Marinova, Snejina, Petrunov, Bogdan, Cvetanov, Jordan, Nenkov, Plamen, Radinov, Atanas, Tchorbadjiiska, Ljubka, Konstantinova, Dora

“…A preparation for the prophylaxis and treatment of inflammations of oral mucosa and parodont Dentavax (D) was investigated in guinea pigs. Animals were given…”
Get full text